cGMP manufacturing services company Pharmaceutics International Inc (Pii) reported on Wednesday the receipt of the US FDA approval for Bretylium Tosylate Injection in USP 500 mg/10 mL (50 mg/mL) Single-Dose Vials for the treatment of ventricular fibrillation.
On 21 December 2018, the US FDA's approval was awarded to the company's partner, Academic Pharmaceuticals Inc.
The company said Bretylium Tosylate Injection is indicated for the prophylaxis and therapy of ventricular fibrillation as well as for the treatment of life-threatening ventricular arrhythmia that has failed to respond to first-line antiarrhythmic agents.
In conjunction, the company is the exclusive manufacturer of Bretylium Tosylate for Academic Pharmaceuticals Inc, who is currently seeking a commercial partner to license and launch the drug product in the US.
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15